- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Forest Labs., LLC v. Sigmapharm Labs., LLC
Plaintiff’s testing of representative ANDA products demonstrated literal infringement.
November 16, 2018
![GENERICally Speaking: A Hatch Waxman Litigation Bulletin](/-/media/images/newsletters/generically-speaking-social-graphics/generically-speaking-nwsltr-badge.jpg?la=en&h=160&w=390&la=en&hash=314B8432ED62E0647D7FC4565EC18B79)
Case Name: Forest Labs., LLC v. Sigmapharm Labs., LLC, Civ. No. 14-cv-1119-MSG, 2018 U.S. Dist. LEXIS 195458 (D. Del. Nov. 16, 2018) (Goldberg, J.)
Drug Product and Patent(s)-in-Suit: Saphris® (asenapine maleate); U.S. Patent No. 5,763,476 (“the ’476 patent”)
Nature of the Case and Issue(s) Presented: Forest manufactured Saphris, a sublingual tablet used to treat schizophrenia and other bipolar-related disorders. Sigmapharm filed an ANDA seeking to market a generic version of Saphris. Forest filed suit, alleging infringement of the ’476 patent, which claimed a pharmaceutical composition of Saphris. After a bench trial, the Court concluded that Sigmapharm’s generic product infringed the ’476 patent.
Why Forest Labs Prevailed: At trial, the parties’ dispute focused on a single issue—whether Sigmapharm’s generic product disintegrated “within 30 seconds in water at 37° Celsius.” Forest Labs took a direct approach to proving its case, devising a 30 and 55 second test demonstrating that the generic tablets did, in fact, disintegrate as claimed. The court found the test, and accompanying expert testimony, persuasive and accurate. Accordingly, the court ruled that Sigmapharm infringed the ’476 patent.
Related Professionals
Christopher A. Pinahs
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.